Estrella Immunopharma, Inc.
ESLA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001844417
No open-market purchases or sales by Estrella Immunopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $4.99M in total; no superinvestor holds it.
Other share classesESLAW
13F holders, Q2 2026
Institutional positions in Estrella Immunopharma, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- −1 vs. Q1 2026
- Shares held
- 4.79M
- −384.6K (−7.4%) vs. Q1 2026
- Total value
- $4.99M
- −$503.5K (−9.2%) vs. Q1 2026
- New holders
- 2
- 4 more added
- Sold out
- 3
- 5 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ESLA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 15 | $4.99M |
| Q1 2026 | 16 | $5.49M |
| Q4 2025 | 15 | $1.56M |
| Q3 2025 | 13 | $878.8K |
| Q2 2025 | 11 | $559.6K |
| Q1 2025 | 11 | $568.4K |
| Q4 2024 | 11 | $341.1K |
| Q3 2024 | 10 | $232.1K |
| Q2 2024 | 7 | $129.2K |
| Q1 2024 | 6 | $165.5K |
| Q4 2023 | 7 | $143.2K |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Estrella Immunopharma, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 3,975,220 | $4.13M | 0.11% | −123,780−3.0% | Reduced |
| Vanguard Capital Management LLC | 416,852 | $433.5K | 0.00% | +34,383+9.0% | Added |
| Geode Capital Management, LLC | 141,321 | $147.0K | 0.00% | −16,164−10.3% | Reduced |
| Vanguard Fiduciary Trust Co | 64,921 | $67.5K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 52,033 | $54.1K | 0.00% | +12,143+30.4% | Added |
| State Street Corp | 43,252 | $45.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 39,100 | $40.7K | 0.00% | −23,695−37.7% | Reduced |
| Northern Trust Corp | 34,861 | $36.3K | 0.00% | +15,237+77.6% | Added |
| US Bancorp | 20,000 | $20.8K | 0.00% | +3,096+18.3% | Added |
| Tower Research Capital LLC (TRC) | 3,308 | $3.44K | 0.00% | −1,551−31.9% | Reduced |
| UBS Group AG | 1,721 | $1.79K | 0.00% | −13,358−88.6% | Reduced |
| Toronto Dominion Bank | 1,089 | $1.13K | 0.00% | 00.0% | Unchanged |
| Wolverine Asset Management LLC | 468 | $487 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 126 | $131 | 0.00% | +126 | New |
| Caitong International Asset Management Co., Ltd | 2 | $2 | 0.00% | +2 | New |
| Wells Fargo & Company | 0 | $0 | 0.00% | −264,388−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −6,600−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −1−100.0% | Sold out |